19673 Investors following Dr Reddys Labs. Share this News with them.
0
Like this story, share it with millions of investors on M3
Not dependent on SALUTAS any more: DRL
GV Prasad, VC & CEO, Dr Reddy's Labs said it is not dependent on SALUTAS any more, reports CNBC-TV18. "We will see improvement in the coming quarters. The Custom Pharmaceutical Services, or CPS, involves making drugs and ingredients specifically for other companies, business saw a de-growth because of the supply situation in Mexico," it added.
Dr Reddys Laboratories has announced its fourth quarter results. The company's Q4 consolidated net profit was at Rs 103 crore versus 325.5 crore (US GAAP).
Its Q4 consolidated net sales were at Rs 1,320 crore versus Rs 1,557.3 crore(US GAAP).
The company's FY08 consolidated net profit stood at Rs 470 crore. DRL Q4FY07 numbers included Zofran Exclusivity (Rs 270 crore).
GV Prasad, Vice Chairman and CEO, Dr Reddy's Labs said it is not dependent on SALUTAS any more, reports CNBC-TV18. "We will see improvement in the coming quarters. The Custom Pharmaceutical Services, or CPS, , which involves making drugs and ingredients specifically for other companies, business saw a de-growth because of the supply situation in Mexico," it added.
Reditux launched in India and is showing good growth, the management added.
Dr Reddys Laboratories 
